

Technical Data

Sabouraud Dextrose Broth

MH033

Intended use

Recommended for cultivation of yeasts, moulds and aciduric microorganisms from pharmaceutical products in accordance with the microbial limit testing by harmonized methodology of USP/EP/BP/JP.

Composition**

Ingredients	g/L
Dextrose (Glucose)	20.000
Mixture of Peptone and Tryptone (1:1)##	10.000
pH after sterilization (at 25°C)	5.6±0.2

Mixture of Peptic digest of animal tissue and Pancreatic digest of casein (1:1)

Directions

Suspend 30.0 grams in 1000 ml purified/distilled water. Heat if necessary to dissolve the medium completely. Dispense into tubes or flasks as desired and sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes or as per validated cycle.

Principle And Interpretation

Fungi were among the first microorganisms recognized because some of the fruiting structures, such as the mushrooms, are large enough to be seen without a microscope. Fungi can be grouped simply on the basis of morphology as either yeasts or moulds (1). Fungal diseases that occur on the skin, hair and mucous membrane are called superficial mycoses, and the organism that cause them, the dermatophytes (2). Where fungi are to be isolated, it is good practice to use a medium that favors their growth but is not optimal for the growth of bacteria.

Sabouraud Dextrose Broth is a modification of Dextrose Agar described by Sabouraud (3). It is useful for the cultivation of fungi. This medium is in accordance with the harmonized method of USP/EP/BP/JP (4-7) and is recommended for microbiological examination of non-sterile products.

Peptone and Tryptone provides nitrogenous, carbonaceous compounds, long chain amino acids and other essential for the growth of fungi. Dextrose (Glucose) acts as the energy source.

Type of specimen

Pharmaceutical samples

Specimen Collection and Handling

For pharmaceutical samples, follow appropriate techniques for sample collection, processing as per pharmaceutical guidelines (4-7). After use, contaminated materials must be sterilized by autoclaving before discarding.

Warning and Precautions

Read the label before opening the container. Wear protective gloves protective clothing/eye protection/face protection. Follow good microbiological lab practices while handing specimens and culture. Standard guidelines should be followed while handling specimens. Safety guidelines may be referred in individual safety data sheets.

Limitations

- 1. For heavily contaminated samples, the medium must be supplemented with inhibitory agents for inhibiting bacterial growth with lower pH.
- 2. Some pathogenic fungi may produce infective spores which are easily dispersed in air, so examination should be carried out in safety cabinet
- 3. Further biochemical tests should be carried out for confirmation.

^{**}Formula adjusted, standardized to suit performance parameters

HiMedia Laboratories Technical Data

Performance and Evaluation

Performance of the medium is expected when used as per the direction on the label within the expiry period when stored at recommended temperature.

Quality Control

Appearance

Cream to yellow homogeneous free flowing powder

Colour and Clarity of prepared medium

Light amber coloured clear solution in tubes

Reaction

pH of 3.0% w/v aqueous solution at 25°C (after sterilization).

pН

5.40-5.80

Growth Promotion Test

Growth Promotion was observed in accordance with the harmonized method of USP/EP/BP/JP after an incubation at 30-35° C for 3-5 days.

Growth promoting properties

Clearly visible growth of microorganism comparable to that previously obtained with previously tested and approved lot of medium occurs at the specified temperature for not more than the shortest period of time specified inoculating 100 cfu (at 30-35°C for 3-5 days).

Cultural Response

Cultural characteristics observed after incubation at 20-25 °C for 3-5 days.

Organism	Inoculum (CFU)	Growth	Incubation temperature	Incubation period	
Candida albicans ATCC 10231 (00054*)	50 -100	luxuriant	30 -35 °C	<=3 d	
Growth Promotion + Total					
Yeast and Mould count					
Candida albicans	50 -100	luxuriant	20 -25 °C	<=5 d	
ATCC 10231 (00054*)					
# Aspergillus brasiliensis	50 -100	luxuriant	20 -25 °C	<=5 d	
ATCC 16404 (00053*)					
Additional Microbiological					
Testing					
Saccharomyces cerevisiae ATCC 9763 (00058*)	50 -100	luxuriant	20 -25 °C	3 -5 d	
\$Saccharomyces kudriavzevii ATCC 2601	50 -100	good-luxuriant	20 -25 °C	3 -5 d	
Candida albicans ATCC 2091 (00055*)	50 -100	luxuriant	20 -25 °C	3 -5 d	

Key: (*) Corresponding WDCM numbers

(#) Formerly known as Aspergillus niger \$Formerly known as Saccharomyces cerevisiae

Storage and Shelf Life

Store between 10-30°C in a tightly closed container and the prepared medium at 15-25°C. Use before expiry date on the label. On opening, product should be properly stored dry, after tightly capping the bottle in order to prevent lump formation due to the hygroscopic nature of the product. Improper storage of the product may lead to lump formation. Store in dry ventilated area protected from extremes of temperature and sources of ignition Seal the container tightly after use. Product performance is best if used within stated expiry period.

Disposal

User must ensure safe disposal by autoclaving and/or incineration of used or unusable preparations of this product. Follow established laboratory procedures in disposing of infectious materials and material that comes into contact with sample must be decontaminated and disposed of in accordance with current laboratory techniques (8,9).

Reference

1.Murray P. R., Baron J. H., Pfaller M. A., Jorgensen J. H. and Yolken R. H., (Ed.), 2003, Manual of Clinical Microbiology, 2.Pelczar M. J., Jr., Reid R. D., Chan E. C. S., 1977, Microbiology, 4th Edi, Tata McGraw-Hill Publishing Company Ltd, New Delhi

3. Sabouraud, 1892, Ann. Dermatol. Syphilol, 3:1061.

- 4. The United States Pharmacopoeia-National Formulatory (USP-NF), 2022.
- 5. The British Pharmacopoeia, 2022, Medicines and Healthcare products Regulatory Agency.
- 6. European Pharmacopoeia, 2022, 10 th volume, European Directorate for the quality of medicines & Healthcare.
- 7. The Japanese Pharmacopoeia, 17th edition, 2016, The Ministry of Health, Labour and welfare.
- 8. Isenberg, H.D. Clinical Microbiology Procedures Handbook, 2nd Edition..
- 9.Jorgensen, J.H., Pfaller, M.A., Carroll, K.C., Funke, G., Landry, M.L., Richter, S.S and Warnock., D.W. (2015) Manual of Clinical Microbiology, 11th Edition. Vol. 1.

Revision: 05/2025

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMediaTM publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMediaTM Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.